Advertisement

Combination index of the concentration and in vivo antagonism activity of racemic warfarin and its metabolites to assess individual drug responses

  • Shuhei Kobayashi
  • Koji Ishii
  • Yasuko Yamada
  • Emi Ryu
  • Junya Hashizume
  • Seiichi Nose
  • Tetsuya Hara
  • Mikiro Nakashima
  • Kaname OhyamaEmail author
Article
  • 34 Downloads

Abstract

The present study was undertaken to examine whether in vivo vitamin K epoxide reductase complex 1 (VKOR) “actual” antagonism activity, calculated by the concentrations and the reported anticoagulant activities of the R- and S-warfarin enantiomers and their metabolites, correlates with the weekly dose of warfarin. Five patients under palliative care were enrolled in our study and 20 serum samples were analyzed by an enantioselective high-performance liquid chromatography–ultraviolet detection method. In vivo VKOR inhibition activities of S-warfarin, R-warfarin, 7- and 10-hydroxywarfarin were calculated as the ratio of drug or metabolite concentration to the IC50. The mean drug concentrations (± SD) of S- and R-warfarin, 7-hydroxywarfarin and 10-hydroxywarfarin were 334 ± 154 ng/ml, 370 ± 115 ng/ml, 42 ± 15 ng/ml and 80 ± 44 ng/ml, respectively. Then, in vivo VKOR actual antagonism activities of S- and R-warfarin, 7-hydroxywarfarin and 10-hydroxywarfarin were calculated. Good correlation (R2 = 0.69–0.72) was obtained between the weekly warfarin dose and the ratios of INR/actual antagonism activity, while poor correlation was observed between the weekly warfarin dose and INR (R2 = 0.32) or the activities (R2 = 0.17–0.21). Actual antagonism activities along with the INR correlated well with the warfarin dose. This parameter may be useful for predicting or altering warfarin doses, although further verification in a larger study is required.

Keywords

Warfarin Hydroxylated warfarin Enantiomer Phenotyping In vivo antagonism activity 

Notes

Acknowledgements

This study was funded by Early-Career Scientists from the Ministry of Education, Culture, Sports, Science and Technology of Japan (Grant Number 18K15393).

Compliance with ethical standards

Conflict of interest

All the authors declare that they have no conflict of interest.

References

  1. 1.
    Breckenridge A, Orme M, Wesseling H, Lewis RJ, Gibbons R (1974) Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. Clin Pharmacol Ther 15:424–430CrossRefGoogle Scholar
  2. 2.
    Toon S, Low LK, Gibaldi M et al (1986) The warfarin-sulfinpyrazone interaction: stereochemical considerations. Clin Pharmacol Ther 39:15–24CrossRefGoogle Scholar
  3. 3.
    Chan E, McLachlan A, O’Reilly R, Rowland M (1994) Stereochemcial aspects of warfarin drug interactions: use of a combined pharmacokinetic-pharmacodynamic model. Clin Pharmacol Ther 56:286–294CrossRefGoogle Scholar
  4. 4.
    Retttie AE, Korzekwa KR, Kunze KL et al (1992) Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role of P450 2C9 in the etiology of (S)-warfarin drug interactions. Chem Res Toxicol 5:54–59CrossRefGoogle Scholar
  5. 5.
    Kaminsky LS, Zhang ZY (1997) Human P450 metabolism of warfarin. Pharmacol Ther 73:67–74CrossRefGoogle Scholar
  6. 6.
    Park BK (1988) Warfain: metabolism and mode of action. Biochem Pharmacol 37:19–27CrossRefGoogle Scholar
  7. 7.
    Yamazaki H, Shimada T (1997) Huamn liver cytochrome P450 enzymes involved in the 7-hydroxylation of R- and S-warfarin enantiomers. Biochem Pharmacol 54:1195–1203CrossRefGoogle Scholar
  8. 8.
    Pokorney SD, Simon DN, Thomas L et al (2016) Stability of international normalized ratios in patients taking long-term warfarin therapy. JAMA 316:661–663CrossRefGoogle Scholar
  9. 9.
    Kamali F, Pirmohamed M (2006) The future prospects of pharmacogenetics in oral anticoagulation therapy. Br J Clin Pharmacol 61:746–751CrossRefGoogle Scholar
  10. 10.
    Schwart UI, Ritchie MD, Bradford Y et al (2008) Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 358:999–1008CrossRefGoogle Scholar
  11. 11.
    Kimmel SE, French B, Kasner SE et al (2013) A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med 369:2283–2293CrossRefGoogle Scholar
  12. 12.
    Kimmel SE (2015) Warfarin Pharmacogenomics: current best evidence. J Thromb Haemost 13(Suppl 1):S266–S271CrossRefGoogle Scholar
  13. 13.
    Anderson JL, Horne BD, Stevens SM et al (2007) Randomized trial for genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 116:2563–2570CrossRefGoogle Scholar
  14. 14.
    Verhoef TI, Ragia G, de Boer A et al (2013) A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon. N Engl J Med 369:2304–2312CrossRefGoogle Scholar
  15. 15.
    Takahashi H, Wilkinson GR, Nutescu EA et al (2006) Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genom 16:101–110CrossRefGoogle Scholar
  16. 16.
    Franco V, Polanczyk CK, Clausell N, Rohde LE (2004) Role of dietary vitamin K intake in chronic oral anticoagulation: prospective evidence from observational and randomized protocols. Am J Med 116:651–656CrossRefGoogle Scholar
  17. 17.
    Hylek EM, Skates SJ, Sheehan MA, Singer DE (1996) An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 335:540–546CrossRefGoogle Scholar
  18. 18.
    Oden A, Fahlen M, Hart RG (2006) Optimal INR for prevention of stroke and death in atrial fibrillation: a critical appraisal. Thromb Res 117:493–499CrossRefGoogle Scholar
  19. 19.
    Singer DE, Chang Y, Fang MC et al (2009) Should patient characteristics influence target anticoagulation intensity for stroke prevention in nonvalvular atrial fibrillation? Circ Cardiovasc Qual Outcomes 2:297–304CrossRefGoogle Scholar
  20. 20.
    Kulkarni UP, Swa BD, Karnad DR et al (2008) A pilot study of the association of pharmacokinetic and pharmacodynamics parameters of warfarin with the dose in patients on long-term anticoagulation. Br J Clin Pharmacol 65:787–790CrossRefGoogle Scholar
  21. 21.
    Miura M, Okuyama S, Kato S et al (2011) Simultaneous determination of warfarin and 7-hydroxywarfarin enantiomers by high-performance liquid chromatography with ultraviolet detection. Ther Drug Monit 33:108–114CrossRefGoogle Scholar
  22. 22.
    Wang X, Hou J, Jann M, Yi Hon Y, Shamsi SA (2013) Development of a chiral micellar electrokinetic chromatography-tandem mass spectrometry assay for simultaneous analysis of warfarin and hydroxywarfarin metabolites: Application to the analysis of patients serum samples. J Chromatogr A 1271:207–216CrossRefGoogle Scholar
  23. 23.
    Haque JA, McDonald MG, Kulman JD, Rettie AE (2014) A cellular system for quantitation of vitamin K cycle activity: structure-activity effects on vitamin K antagonism by warfarin metabolites. Blood 123:582–589CrossRefGoogle Scholar
  24. 24.
    Locatelli I, Kmetec V, Mrhar A, Grabnar I (2005) Determination of warfarin enentiomers and hydroxylated metabolites in human blood plasma by liquid chromatography with achiral and chiral separation. J Chromatogr B 818:191–198CrossRefGoogle Scholar
  25. 25.
    Regalado EL, Schariter JA, Welch CJ (2014) Investigation of two-dimensional high performance liquid chromatography approaches for reversed phase resolution of warfarin and hydroxywarfarin isomers. J Chromatogr A 1363:200–206CrossRefGoogle Scholar
  26. 26.
    Zuo Z, Wo SK, Lo CMY, Zhou L, Cheng G, You JHS (2010) Simultaneous measurement of S-warfarin, R-warfarin, S-7-hydroxywarfarin and R-7-hydroxywarfarin in human plasma by liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 52:305–310CrossRefGoogle Scholar
  27. 27.
    Mushiroda T, Ohnishi Y, Saito S et al (2006) Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients. J Hum Genet 51:249–253CrossRefGoogle Scholar
  28. 28.
    Jones DR, Kim SY, Guderyon M, Yun CH, Moran JH, Miller GP (2010) Hydroxywarfarin metabolites potently inhibit CYP2C9 metabolism of S-warfarin. Chem Res Toxicol 23:939–945CrossRefGoogle Scholar
  29. 29.
    Miura M, Takahashi N, Kanno S et al (2011) Drug interaction of (S)-warfarin, and not (R)-warfarin, with itraconazole in a hematopoietic stem cell transplant recipient. Clin Chim Acta 412:2002–2006CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.School of Pharmaceutical SciencesNagasaki UniversityNagasakiJapan
  2. 2.Department of AnesthesiologyNagasaki University School of MedicineNagasakiJapan
  3. 3.Analytical and Quality Evaluation Research LaboratoriesDaiichi Sankyo Co., Ltd.HiratsukaJapan
  4. 4.Department of PharmacyNagasaki University HospitalNagasakiJapan
  5. 5.Unit of Medical Pharmacy, Department of Pharmacy Practice, Graduate School of Biomedical SciencesNagasaki UniversityNagasakiJapan

Personalised recommendations